Oxford Nanopore Technologies shares climbed 6.6% to 130.2p following the release of its full interim results for the six months ended June 30, 2026. The announcement, scheduled for the day, attracted particular scrutiny after a trading update in July pushed the stock to a 52-week low near 95.7p.
The financials confirmed the revenue shortfall that market participants had already priced in. However, the results contained stronger-than-expected signs on profitability. Gross margin widened by 400 basis points to 62.2%, and adjusted EBITDA losses more than halved to A322.1 million from A348.3 million a year earlier. The company also reported that adjusted operating costs fell by nearly 7% year-on-year.
Management unveiled a new global cross-licensing agreement that is expected to deliver $20 million in licensing fees in the second half of FY26. In addition, the company disclosed $15 million of committed product purchases spread across FY27 and FY28. Those contractually backed inflows represent explicit, near-term revenue catalysts cited by the company.
Operational highlights in the interim results included a 35.4% increase in clinical revenue and continued momentum in the BioPharma segment, both of which the company flagged as high-value market areas on a strong trajectory.
On the sell-side front, Berenberg kept its Buy recommendation but trimmed its price target to A32.00 from A32.20, citing persistent revenue headwinds originating from China and the Middle East.
Macro and market context offered little directional influence on the move. The FTSE 100 was essentially flat on the day. UK inflation data for July showed the consumer price index rising to 2.9% year-on-year from 2.6% in June, in line with expectations. That print produced a modest pullback in Bank of England rate-hike bets but did not exert any meaningful, sector-specific effect on genomics stocks according to market commentary in the release.
Investors appeared to price the combined impact of the improved margin profile and the licensing agreement alongside the company e2 80 99s discounted valuation - the stock remains well below its 52-week high of 215.6p - and reassessed the trajectory toward the firm e2 80 99s stated goal of achieving adjusted EBITDA breakeven in 2027. The company e2 80 99s nearer-term cash commitments from the licensing deal and product purchase agreements contributed to the more constructive investor reaction.
What investors and analysts are watching next
- Revenue trends in China and the Middle East, which Berenberg flagged as ongoing headwinds.
- Execution against the timeline to reach adjusted EBITDA breakeven in 2027.
- Progress in clinical and BioPharma end markets that drove 35.4% clinical revenue growth within the interim period.